




Instance: composition-en-acef8cbcdfca211b39877dbdf094e7e6
InstanceOf: CompositionUvEpi
Title: "Composition for coagadex Package Leaflet"
Description:  "Composition for coagadex Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp10bd167afc53bad0ebe6f2f458a35915)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - coagadex"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Coagadex is and what it is used for  </li>
<li>What you need to know before you use Coagadex   </li>
<li>How to use Coagadex </li>
<li>Possible side effects  </li>
<li>How to store Coagadex   </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What coagadex is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What coagadex is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Coagadex is a concentrate of human coagulation factor X, a protein that is needed for blood to clot. The 
factor X in Coagadex is extracted from human plasma (the liquid part of blood). It is used to treat and 
prevent bleeding in patients with hereditary factor X deficiency, including during surgery.  </p>
<p>Patients with factor X deficiency do not have sufficient factor X for their blood to clot properly, leading to 
excessive bleeding. Coagadex replaces the missing factor X and allows their blood to clot normally.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Coagadex:</p>
<ul>
<li>if you are allergic to human coagulation factor X or any of the other ingredients of this medicine 
(listed in section 6).<br />
Check with your doctor if you think this applies to you. </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor, pharmacist or nurse before using Coagadex:</p>
<ul>
<li>if you have a larger or longer bleed than usual and the bleeding does not stop after an injection of 
Coagadex. </li>
<li>if you are taking a medicine to prevent blood clotting that works by blocking clotting factor Xa. These 
medicines may prevent Coagadex from working. </li>
</ul>
<p>Some patients with a shortage of factor X may develop inhibitors (antibodies) to factor X during treatment. 
This could mean that the treatment will not work properly. Your doctor will check regularly for the 
development of these antibodies, and especially before an operation. Both before and after treatment with this 
medicine, particularly for your first course of treatment, your doctor will probably carry out tests to check the 
level of factor X in your blood. 
Virus safety 
When medicines are made from human blood or plasma, certain measures are put in place to prevent 
infections being passed on to recipients. These include: </p>
<p>careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, 
  the testing of donated plasma for signs of virus/infections, 
  the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. </p>
<p>The measures taken are considered effective for the following viruses: human immunodeficiency virus 
(HIV), hepatitis B virus, hepatitis C virus, hepatitis A virus and parvovirus B19. Despite these measures, 
when medicines prepared from human blood or plasma are administered, the possibility of passing on an 
infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of 
infections. </p>
<p>It is strongly recommended that every time you receive a dose of Coagadex, the name and batch number of 
the product are recorded in order to maintain a record of the batches used. </p>
<p>Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly or 
repeatedly receive human plasma-derived factor X products. </p>
<p>Children and adolescents 
The listed warnings and precautions for adults also apply to children (aged 2 to 11 years) and adolescents 
(aged 12 to 18 years). </p>
<p>Other medicines and Coagadex 
Tell your doctor if you are taking, have recently taken or might take any other medicines.  </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor or pharmacist for advice before using this medicine. </p>
<p>Driving and using machines 
There are no known effects of this medicine on the ability to drive or operate machinery. </p>
<p>Coagadex contains sodium 
This medicine contains up to 9.2 mg sodium (the main component of cooking/table salt) in each millilitre of 
solution. This is equivalent to 0.0046% of the recommended maximum daily dietary intake of sodium for an 
adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your treatment should be initiated by a doctor who is experienced in the treatment of bleeding disorders. </p>
<p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure.  </p>
<p>Coagadex should be injected directly into a vein. Before injecting this medicine at home, you should have 
received training by your healthcare professional on how to do so.  </p>
<p>Your doctor will explain to you how much you should use, when you should use it and for how long. Your 
doctor will usually tell you your dose in terms of the number of full vials that supply the dose most suited to 
you. Not more than 60 IU/kg daily should be administered in any age group. </p>
<p>Use in adults </p>
<p>How much Coagadex is given to treat a bleed or prevent further bleeding? 
Your doctor will tell you how much Coagadex to administer to treat a bleed and to prevent further bleeding; 
the dose required will depend on your normal blood level of factor X </p>
<p>How much is given before, during and after major surgery? 
Before: The dose of Coagadex used should be sufficient to raise your blood factor X level to between 70 and 
90 units/dL. The dose you need will depend on your normal blood level of factor X and will be calculated by 
your doctor. </p>
<p>After: During the first few days after the operation, your plasma factor X concentration will be checked 
regularly. It is recommended that your blood factor X level is kept above 50 units/dL. The dose you need 
will be calculated by your doctor. </p>
<p>If your blood factor X concentration is too low (this will be tested by your doctor), or if it decreases faster 
than expected, an inhibitor to factor X may be present which stops the medicine from working properly. 
Your doctor will arrange for the appropriate laboratory tests to see if this is the case. </p>
<p>How much is given regularly for long-term prevention of bleeds? 
Your doctor will advise if this use is suitable for you and, if so, of the appropriate dose. </p>
<p>Use in children and adolescents 
Your doctor will recommend an appropriate dose for you or your child. Doses for children less than 12 years 
old are generally larger than for adolescents and adults. Doses for adolescents will be similar to those for 
adults. </p>
<p>When to inject Coagadex 
* The medicine should be injected when the first sign of bleeding occurs. 
* The injection should be repeated as necessary to stop the bleeding. 
* Each individual bleed should be judged on its own severity. 
* If you are using this medicine for the first time, your doctor will supervise you. </p>
<p>Dissolving your medicines before use 
Your medicine must only be dissolved in the solvent provided with the product. </p>
<p>Quantity of Coagadex 
Volume of solvent 
250 IU 
2.5 mL 
500 IU 
5 mL </p>
<p>Coagadex is supplied with the amount of solvent as shown in the table. </p>
<p>You can dissolve this medicine using the needle-free Mix2Vial transfer device included within each pack.<br />
Bring the containers of Coagadex to room temperature before mixing. 
Make up the medicine as follows: </p>
<p>Step 1 
  Remove the cap from the powder vial and clean the top of the 
stopper with an alcohol swab. 
  Repeat this step with the vial of solvent. 
  Peel back the top of the transfer device package but leave the device in the 
package. </p>
<p>Step 2 
  Place the blue end of the transfer device on the solvent vial and push straight 
down until the spike penetrates the rubber stopper and snaps into place. 
  Remove the plastic outer packaging from the transfer device and discard it, 
taking care not to touch the exposed end of the device. </p>
<p>Step 3 
  Turn the solvent vial upside down with the device still attached. 
  Place the clear end of the transfer device on the powder vial and push 
straight down until the spike penetrates the rubber stopper and snaps into 
place. </p>
<p>Step 4 
  The solvent will be pulled into the powder vial by the vacuum contained 
within it. 
  Gently swirl the vial to make sure the powder is thoroughly mixed. Do not 
shake the vial. 
  A colourless, clear or slightly pearl-like solution should be obtained, usually 
in about 1 minute (5 minutes maximum). </p>
<p>Step 5 
  Separate the empty solvent vial and blue part of the transfer device from the 
clear part by unscrewing anti-clockwise. 
  Take an empty syringe (not provided in the Coagadex pack) and draw air 
into it by pulling the plunger to match the required volume of water added in 
step 4.   Connect the syringe to the clear part of the transfer device and push the air 
in the syringe into the vial. </p>
<p>Step 6 
  Immediately invert the vial of solution, which will be drawn into the 
syringe. 
  Disconnect the filled syringe from the device. 
  The product is now ready for use. Follow the normal safety practices for 
administration. Make sure you use the product within an hour after it has been 
made up. </p>
<p>Do not use this medicine:</p>
<ul>
<li>
<p>if the solvent is not pulled into the vial (this indicates loss of vacuum in the vial, so the 
powder must not be used). </p>
</li>
<li>
<p>if the dissolved powder and solvent form a gel or a clot (if this happens please tell your healthcare 
provider, reporting the batch number printed on the vial). </p>
</li>
</ul>
<p>If you use more Coagadex than you should 
If you administer more of this medicine than your doctor prescribed, it is possible you might develop a blood 
clot. If you think you may be using too much, stop the injection and tell the doctor, pharmacist or nurse. If 
you know you have used too much, tell the doctor, pharmacist or nurse as soon as possible.  </p>
<p>If you forget to use Coagadex 
Do not use a double dose to make up for a forgotten dose. Inject your normal dose as you remember and then 
continue dosing as instructed by your doctor. </p>
<p>If you stop using Coagadex 
Always consult your doctor before deciding to stop your treatment. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Allergic reactions (hypersensitivity reactions) have occurred rarely in the treatment of bleeding disorders 
with similar medicines (affecting up to 1 in 1,000 people), and sometimes progress to shock. Signs of these 
may include skin rash (including hives), tingling, flushing, nausea, vomiting, headache, cough, wheezing, 
tightness of the chest, chills, fast heart rate, dizziness, lethargy, restlessness, swelling of the face, tightness of 
the throat, discomfort at the site of injection.<br />
If you get any of these contact your doctor.  </p>
<p>The following side effects have been reported with Coagadex. </p>
<p>Common (may affect up to 1 in 10 people): 
* pain or redness at site of injection 
* tiredness 
* back pain </p>
<p>Side effects in children and adolescents 
Side effects in children are expected to be the same as in adults. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. </p>
<p>By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the containers after  EXP . The expiry date 
refers to the last day of that month. </p>
<p>Do not store above 30 C.   </p>
<p>Do not freeze.  </p>
<p>Keep container in the outer carton in order to protect it from light. </p>
<p>Do not use this medicine if you notice small bits in the dissolved product. Once made up, Coagadex must be 
used within one hour.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Your treatment centre will provide a 
special container to dispose of any solution that remains, any used syringes, needles and empty containers. 
These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Coagadex contains<br />
- The active substance is human coagulation factor X. One vial contains nominally 250 IU or 500 IU 
human coagulation factor X. 
- The other ingredients are: citric acid, disodium phosphate dihydrate, sodium chloride,<br />
sodium hydroxide and sucrose (see section 2 for further information about ingredients).<br />
- Solvent:  water for injections. </p>
<p>What Coagadex looks like and contents of the pack 
Coagadex is a white or off-white powder and is packed in quantities of 250 IU and 500 IU. After being made 
up, the solution is colourless, clear or pearl-like (opalescent). Before injection, look at the solution. If the 
solution is cloudy or has any particles, do not use it. </p>
<p>A transfer device called Mix2Vial is also provided. </p>
<p>Contents of the 250 IU pack 
1 vial 250 IU powder 
1 vial 2.5 mL water for injections 
1 Transfer Device (Mix2Vial) </p>
<p>Contents of the 500 IU pack 
1 vial 500 IU powder 
1 vial 5 mL water for injections 
1 Transfer Device (Mix2Vial) </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
BPL Bioproducts Laboratory GmbH 
Dornhofstra e 34, 63263 Neu-Isenburg 
Germany </p>
<p>Manufacturer 
PharmaKorell GmbH, Georges-K hler-Str. 2, 79539 L rrach, Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Bio Products Laboratory Ltd 
T l/Tel: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(Royaume-Uni/Verenigd 
Koninkrijk/Gro britannien) </p>
<p>Lietuva 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Jungtin  Karalyst ) </p>
<p>Bio Products Laboratory Ltd 
Te .: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(   ) </p>
<p>Luxembourg/Luxemburg 
Bio Products Laboratory Ltd 
T l/Tel: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(Royaume-Uni/Verenigd 
Koninkrijk/Gro britannien) </p>
<p>esk  republika 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Velk  Brit nie) </p>
<p>Magyarorsz g 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Egyes lt Kir lys g) </p>
<p>Danmark 
Bio Products Laboratory Ltd 
Tfl: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannien) </p>
<p>Malta 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ir Renju Unit) </p>
<p>Deutschland 
BPL Bioproducts Laboratory GmbH<br />
Tel: +49 (0) 2408 146 0e-mail: bpl@medwiss-extern.de 
Deutschland </p>
<p>Nederland 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Verenigd Koninkrijk) </p>
<p>Eesti 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
( hendkuningriik) </p>
<p>Norge 
Bio Products Laboratory Ltd 
Tlf: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannia) </p>
<p>Bio Products Laboratory Ltd 
 : +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(   ) </p>
<p>sterreich 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Gro britannien) 
Espa a 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Reino Unido) </p>
<p>Polska 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Wielka Brytania) </p>
<p>France 
Laboratoire Cevidra 
Tel: +33 493705e-mail: contact@cevidra.com 
France </p>
<p>Portugal 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Reino Unido) </p>
<p>Hrvatska 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ujedinjeno Kraljevstvo) </p>
<p>Rom nia 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Marea Britanie) 
Ireland 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(United Kingdom) 
Slovenija 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Zdru eno kraljestvo) 
 sland 
Bio Products Laboratory Ltd 
S mi: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Bretland) </p>
<p>Slovensk  republika 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Spojen  kr ovstvo) </p>
<p>Italia 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Regno Unito) </p>
<p>Suomi/Finland 
Bio Products Laboratory Ltd 
Puh/Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Iso-Britannia) </p>
<p>Bio Products Laboratory Ltd 
 : +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(   ) </p>
<p>Sverige 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannien) </p>
<p>Latvija 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Lielbrit nija)<br />
United Kingdom (Northern Ireland) 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
United Kingdom </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-acef8cbcdfca211b39877dbdf094e7e6
InstanceOf: CompositionUvEpi
Title: "Composition for coagadex Package Leaflet"
Description:  "Composition for coagadex Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp10bd167afc53bad0ebe6f2f458a35915)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - coagadex"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at bruge Coagadex<br />
3. Sådan skal du bruge Coagadex 
4. Bivirkninger<br />
5. Opbevaring af Coagadex<br />
6. Pakningsstørrelse og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What coagadex is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What coagadex is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Coagadex er et koncentrat af human koagulationsfaktor X, et protein, der kræves for at blod kan størkne. 
Faktor X i Coagadex udvindes af humant plasma (den flydende del af blodet). Det anvendes til at 
behandle og forebygge blødninger hos patienter med arvelig faktor X-mangel, bl.a. under operation.  </p>
<p>Patienter med faktor X-mangel har ikke tilstrækkelig faktor X i deres blod til, at det kan størkne rigtigt, 
hvilket fører til overdrevet blødning. Coagadex erstatter den manglende faktor X og gør, at blodet 
størkner normalt. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Coagadex:</p>
<ul>
<li>hvis du er allergisk over for human koagulationsfaktor X eller et af de øvrige indholdsstoffer i 
dette lægemiddel (angivet i afsnit 6).<br />
Spørg din læge, hvis du mener, at dette gælder for dig. </li>
</ul>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Coagadex:</p>
<ul>
<li>hvis du har større eller længere blødning end normalt, og blødningen ikke stopper efter injektion af 
Coagadex. </li>
<li>hvis du tager medicin til forebyggelse af blodpropper, som virker ved at blokere faktor Xa. Denne 
medicin kan forhindre Coagadex i at virke. </li>
</ul>
<p>Nogle patienter med faktor X-mangel kan udvikle hæmmere (immunstoffer) over for faktor X under 
behandling. Dette kan betyde, at behandlingen ikke virker efter hensigten. Lægen vil regelmæssigt 
kontrollere udviklingen af disse immunstoffer - særligt før en operation. Din læge vil sikkert, både før 
og efter behandling med dette lægemiddel, - særligt ved dit første behandlingsforløb - udføre tests for 
at kontrollere koncentrationen af faktor X i dit blod. </p>
<p>Virussikkerhed 
Når lægemidler fremstilles af humant blod eller plasma, tages der visse forholdsregler for at forhindre, 
at infektioner overføres til modtageren. Disse omfatter: </p>
<ul>
<li>omhyggelig udvælgelse af blod- og plasmadonorer for at sikre, at de, der risikerer at være inficerede, 
udelukkes, </li>
<li>testning af doneret plasma for tegn på virus/infektioner, </li>
<li>inklusion af trin i behandlingen af blod eller plasma, som kan inaktivere eller fjerne vira. </li>
</ul>
<p>De foranstaltninger, der træffes, anses som effektive over for følgende vira: human immundefekt virus 
(HIV), hepatitis B-virus, hepatitis C-virus, hepatitis A-virus or parvovirus B19. Trods disse 
foranstaltninger, kan muligheden for overførsel af en infektion ikke helt udelukkes, når lægemidler, som 
er fremstillet af humant blod eller plasma, administreres. Dette gælder også for alle ukendte eller nye 
vira eller andre typer infektioner. </p>
<p>Det anbefales på det kraftigste, at produktets navn og batchnummer registreres, hver gang du får en 
dosis Coagadex®, for at føre regnskab med hvilke batch der er brugt. </p>
<p>Din læge vil eventuelt anbefale, at du overvejer at blive vaccineret mod hepatitis A og B, hvis du 
regelmæssigt eller gentagne gange får human plasma-afledt faktor X-produkter. </p>
<p>Børn og unge 
De anførte advarsler og forholdsregler for voksne gælder også for børn (mellem 2 og 11 år) samt unge 
(mellem 12 og 18 år). </p>
<p>Brug af anden medicin sammen med Coagadex 
Fortæl altid lægen, hvis du tager anden medicin, for nylig har taget anden medicin eller planlægger at 
tage anden medicin. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonale til råds, før du bruger dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Der er ingen kendte virkninger af dette lægemiddel på evnen til at køre eller betjene maskiner. </p>
<p>Coagadex indeholder natrium 
Dette lægemiddel indeholder op til 9,2 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
milliliter opløsning. Dette svarer til 0,0046 % af den anbefalede maksimale daglige indtagelse af 
natrium i kosten for en voksen. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Din behandling skal igangsættes af en læge, som har erfaring med behandling af blødningsforstyrrelser. </p>
<p>Brug altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Coagadex skal injiceres direkte ind i en blodåre. Før injektion af denne medicin derhjemme, skal du af 
sundhedspersonalet have modtaget instrukser i, hvordan man gør det.  </p>
<p>Lægen vil forklare dig, hvor meget du skal bruge, hvornår du skal bruge det og hvor længe. Lægen vil 
normalt angive din dosis som det antal hele hætteglas, der giver dig den dosis, der passer bedst til dig. 
Der må ikke administreres over 60 IE/kg dagligt hos nogen aldersgruppe. </p>
<p>Brug til voksne </p>
<p>Hvor meget Coagadex gives til behandling af en blødning eller for at forhindre yderligere 
blødning? 
Lægen vil fortælle dig, hvor meget Coagadex du skal administrere, for at behandle en blødning eller 
forhindre yderligere blødning; den påkrævede dosis vil afhænge af dit blods normale faktor X-niveau </p>
<p>Hvor meget gives før, under og efter en større operation? 
Før: Den dosis Coagadex, der anvendes, bør være tilstrækkelig til at hæve blodets faktor X-niveau til 
mellem 70 og 90 enheder/dl. Den dosis, du har brug for, afhænger af dit blods normale factor X-
niveau og beregnes af din læge. </p>
<p>Efter: I løbet af de første par dage efter operationen, vil din plasma faktor X-koncentration blive 
kontrolleret regelmæssigt. Det anbefales, at dit blods faktor X-niveau holdes over 50 enheder/dl. Den 
dosis du har brug for, vil blive beregnet af din læge. </p>
<p>Hvis dit blods faktor X-koncentration er for lav (dette testes af lægen), eller hvis den falder hurtigere 
end forventet, kan der være en faktor X-hæmmer til stede, som forhindrer medicinen i at virke rigtigt. 
Din læge vil sørge for de nødvendige laboratorieprøver for at se, om dette er tilfældet. </p>
<p>Hvor meget gives der regelmæssigt til langtidsforebyggelse af blødninger? 
Din læge vil fortælle, om dette er passende for dig, og i så fald angive den passende dosis. </p>
<p>Brug til børn og unge <br />
Lægen vil anbefale en passende dosis til dig eller dit barn. Doser til børn under 12 år er generelt større 
end doser til unge og voksne. Doser til unge vil svare til doserne til voksne. </p>
<p>Hvornår skal Coagadex injiceres? </p>
<ul>
<li>
<p>Lægemidlet bør injiceres ved første tegn på blødning. </p>
</li>
<li>
<p>Injektionen bør gentages efter behov for at stoppe blødningen. </p>
</li>
<li>
<p>Hver enkelt blødning bør bedømmes efter dens individuelle sværhedsgrad. </p>
</li>
<li>
<p>Hvis du benytter lægemidlet for første gang, vil lægen vejlede dig. </p>
</li>
</ul>
<p>Opløsning af medicin før brug 
Medicinen må kun opløses i opløsningsmidlet, som leveres sammen med produktet. </p>
<p>Mængde af Coagadex 
Mængde opløsningsmiddel 
250 IE 
2,5 ml 
500 IE 
5 ml </p>
<p>Coagadex leveres med den mængde opløsningsmiddel, der er vist i tabellen. </p>
<p>Du kan opløse medicinen med den nålefri Mix2Vial-overførselsenhed, som er inkluderet i hver pakke.<br />
Bring beholderne med Coagadex til stuetemperatur før blanding. </p>
<p>Bland lægemidlet som følger: </p>
<p>Trin 1 
• Fjern hætten fra hætteglasset med pulver og rengør toppen af 
proppen med en spritserviet. 
• Gentag dette trin med hætteglasset med opløsningsmidlet. 
• Pil toppen af pakken af med overførselsenheden men lad enheden blive i 
pakken. </p>
<p>Trin 2 
• Placér den blå ende af overførselsenheden på hætteglasset med 
opløsningsmiddel og skub lige ned, indtil spidsen trænger igennem 
gummiproppen og klikker på plads. 
• Fjern den ydre plastikemballage fra overførselsenheden kassér den og pas på 
ikke at berøre den eksponerede ende af enheden. </p>
<p>Trin 3 
• Vend hætteglasset med opløsningsmiddel på hovedet, mens enheden stadig 
er fastgjort. 
• Placér den klare ende af overførselsenheden på pulverhætteglasset og skub 
lige ned, indtil spidsen trænger igennem gummiproppen og klikker på plads. </p>
<p>Trin 4 
• Opløsningsmidlet vil blive trukket ind i pulverhætteglasset vha. vakuummet 
heri. 
• Bevæg forsigtigt glasset rundt for at sikre, at pulveret blandes godt. 
Hætteglasset må ikke rystes. 
• Der skal opnås en farveløs, klar eller let perlemorslignende opløsning, som 
regel på omkring 1 minut (maksimalt 5 minutter). </p>
<p>Trin 5 
• Adskil det tomme hætteglas med opløsningsmiddel og den blå del af 
overførselsenheden fra den klare del ved at skrue af mod uret.<br />
• Tag en tom sprøjte (medfølger ikke i pakningen med Coagadex), og træk 
luft ind i den ved at trække stemplet tilbage svarende til den krævede mængde 
vand, der blev tilsat i trin 4. • Tilslut sprøjten til den klare del af overførselsenheden, og pres luften fra 
sprøjten ind i hætteglasset. </p>
<p>Trin 6 
• Vend straks hætteglasset med opløsningen på hovedet. Opløsningen vil 
blive trukket ind i sprøjten. 
• Fjern den fyldte sprøjte fra enheden. 
• Produktet er nu klart til brug. Følg de gængse sikkerhedsforanstaltninger for 
administration. Sørg for at anvende produktet inden for en time efter, at det er 
blandet. </p>
<p>Dette lægemiddel må ikke benyttes, hvis:</p>
<ul>
<li>
<p>opløsningsmidlet ikke trækkes ind i hætteglasset (dette indikerer tab af vakuum i hætteglasset, så 
pulveret må ikke benyttes). </p>
</li>
<li>
<p>det opløste pulver og opløsningsmidlet danner en gel eller en klump (hvis dette sker, så fortæl det 
til dit sundhedspersonale og angiv batchnummeret, som er trykt på hætteglasset). </p>
</li>
</ul>
<p>Hvis du har taget for meget Coagadex<br />
Hvis du tager mere af dette lægemiddel end din læge har ordineret, er det muligt, at du vil danne en 
blodprop. Hvis du mener, at du tager for meget, skal du stoppe injektionen og fortælle det til lægen, 
apotekspersonalet eller sundhedspersonalet. Hvis du ved, at du har taget for meget, skal du fortælle det 
til lægen, apotekspersonalet eller sundhedspersonalet så hurtigt som muligt. </p>
<p>Hvis du har glemt at tage Coagadex 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Du skal injicere den normale 
dosis, når du kommer i tanke om det og fortsætte doseringen som anvist af lægen. </p>
<p>Hvis du holder op med at tage Coagadex 
Rådfør dig altid med lægen, før du beslutter at stoppe din behandling. </p>
<p>Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Allergiske 
reaktioner 
(overfølsomhedsreaktioner) 
ses 
sjældent 
hos 
behandlingen 
af 
blødningsforstyrrelser med lignende medicin (påvirker op til 1 ud af 1.000 personer), og udvikler sig 
nogle gange til chok. Tegn på disse kan omfatte udslæt (herunder nældefeber), prikken, rødmen, kvalme, 
opkastning, hovedpine, hoste, hvæsen, trykken for brystet, kulderystelser, hurtig puls, svimmelhed, 
sløvhed, rastløshed, hævelse i ansigtet, stramning i halsen, ubehag omkring injektionsstedet.<br />
Hvis du oplever nogen af disse, skal du kontakte lægen.  </p>
<p>Følgende bivirkninger er blevet indberettet med Coagadex. </p>
<p>Almindelig (kan påvirke op til 1 ud af 10 mennesker): </p>
<ul>
<li>
<p>smerter eller rødmen omkring injektionsstedet </p>
</li>
<li>
<p>træthed </p>
</li>
<li>
<p>rygsmerter </p>
</li>
</ul>
<p>Bivirkninger hos børn og unge 
Bivirkninger hos børn forventes at være de samme som hos voksne. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V.  </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden 
af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store coagadex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store coagadex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter "EXP". Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. </p>
<p>Må ikke nedfryses. </p>
<p>Opbevares i den ydre karton for at beskytte mod lys. </p>
<p>Brug ikke lægemidlet, hvis du bemærker små stykker i det opløste produkt. Når  er blandet, skal det 
benyttes inden for en time.  </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Behandlingscentret vil give dig en særlig 
beholder til bortskaffelse af eventuel resterende opløsning, ubrugte sprøjter, kanyler og tomme 
beholdere. Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller 
skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Coagadex indeholder:</h2>
<p>Aktivt stof/aktive stoffer: human koagulationsfaktor X. Et hætteglas indeholder normalt 250 IE 
eller 500 IE human koagulationsfaktor X. 
- 
Øvrige indholdsstoffer: citronsyre, dinatriumfosfatdihydrat, natriumklorid, natriumhydroxid og 
sakkarose (se afsnit 2 for yderligere information om indholdsstoffer). 
- 
Opløsningsmiddel: vand til injektionsvæske.  </p>
<p>Udseende og pakningsstørrelser 
Coagadex er en/et hvidt eller råhvidt pulver og er pakket i mængder på 250 IE og 500 IE. Efter blanding 
er opløsningsmidlet gennemsigtigt eller perleagtigt (opaliserende). Se på opløsningen før injektion. Hvis 
opløsningen er grumset eller indeholder partikler må den ikke benyttes. </p>
<p>Der medfølger desuden en overførselsenhed, Mix2Vial. </p>
<p>Indhold af pakningen med 250 IE 
1 hætteglas 250 IE pulver 
1 hætteglas 2,5 ml vand til injektionsvæske 
1 overførselsenhed (Mix2Vial) </p>
<p>Indhold af pakningen med 500 IE 
1 hætteglas 500 IE pulver 
1 hætteglas 5 ml vand til injektionsvæske 
1 overførselsenhed (Mix2Vial) </p>
<p>Begge pakningsstørrelser er ikke nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
BPL Bioproducts Laboratory GmbH 
Dornhofstraße 34, 63263 Neu-Isenburg 
Tyskland </p>
<p>Fremstiller 
PharmaKorell GmbH, Georges-Köhler-Str. 2, 79539 Lörrach, Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Bio Products Laboratory Ltd 
Tél/Tel: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(Royaume-Uni/Verenigd 
Koninkrijk/Großbritannien) </p>
<p>Lietuva 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Jungtinė Karalystė) </p>
<p>България 
Bio Products Laboratory Ltd 
Teл.: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(Обединено кралство) </p>
<p>Luxembourg/Luxemburg 
Bio Products Laboratory Ltd 
Tél/Tel: + 44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk<br />
(Royaume-Uni/Verenigd 
Koninkrijk/Großbritannien) </p>
<p>Česká republika 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Velká Británie) </p>
<p>Magyarország 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Egyesült Királyság) 
Danmark 
Bio Products Laboratory Ltd 
Tfl: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannien) </p>
<p>Malta 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ir Renju Unit) </p>
<p>Deutschland 
BPL Bioproducts Laboratory GmbH<br />
Tel: +49 (0) 2408 146 0e-mail: bpl@medwiss-extern.de 
Deutschland </p>
<p>Nederland 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Verenigd Koninkrijk) </p>
<p>Eesti 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ühendkuningriik) </p>
<p>Norge 
Bio Products Laboratory Ltd 
Tlf: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannia) </p>
<p>Ελλάδα 
Bio Products Laboratory Ltd 
Τηλ: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ηνωμένο Βασίλειο) </p>
<p>Österreich 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Großbritannien) 
España 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Reino Unido) </p>
<p>Polska 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Wielka Brytania) </p>
<p>France 
Laboratoire Cevidra 
Tel: +33 493705e-mail: contact@cevidra.com 
France </p>
<p>Portugal 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Reino Unido) </p>
<p>Hrvatska 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ujedinjeno Kraljevstvo) </p>
<p>România 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Marea Britanie) 
Ireland 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(United Kingdom) 
Slovenija 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Združeno kraljestvo) 
Ísland 
Bio Products Laboratory Ltd 
Sími: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Bretland) </p>
<p>Slovenská republika 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Spojené kráľovstvo) </p>
<p>Italia 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Regno Unito) </p>
<p>Suomi/Finland 
Bio Products Laboratory Ltd 
Puh/Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Iso-Britannia) </p>
<p>Κύπρος 
Bio Products Laboratory Ltd 
Τηλ: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Ηνωμένο Βασίλειο) </p>
<p>Sverige 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Storbritannien) </p>
<p>Latvija 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
(Lielbritānija)<br />
United Kingdom (Northern Ireland) 
Bio Products Laboratory Ltd 
Tel: +44 (0) 20 8957 2e-mail: medinfo@bpl.co.uk 
United Kingdom </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
http://www.ema.europa.eu hjemmeside og på Sundhedsstyrelsens hjemmeside http://www.sst.dk/ </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-acef8cbcdfca211b39877dbdf094e7e6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for coagadex Package Leaflet for language en"
Description: "ePI document Bundle for coagadex Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-acef8cbcdfca211b39877dbdf094e7e6"
* entry[0].resource = composition-en-acef8cbcdfca211b39877dbdf094e7e6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpacef8cbcdfca211b39877dbdf094e7e6"
* entry[=].resource = mpacef8cbcdfca211b39877dbdf094e7e6
                            
                    
Instance: bundlepackageleaflet-da-acef8cbcdfca211b39877dbdf094e7e6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for coagadex Package Leaflet for language da"
Description: "ePI document Bundle for coagadex Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-acef8cbcdfca211b39877dbdf094e7e6"
* entry[0].resource = composition-da-acef8cbcdfca211b39877dbdf094e7e6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpacef8cbcdfca211b39877dbdf094e7e6"
* entry[=].resource = mpacef8cbcdfca211b39877dbdf094e7e6
                            
                    



Instance: mpacef8cbcdfca211b39877dbdf094e7e6
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Coagadex 250 IU powder and solvent for solution for injection"
Description: "Coagadex 250 IU powder and solvent for solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/16/1087/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Coagadex 250 IU powder and solvent for solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: acef8cbcdfca211b39877dbdf094e7e6ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "coagadex"

* status = #current
* mode = #working

* title = "List of all ePIs associated with coagadex"

* subject = Reference(mp10bd167afc53bad0ebe6f2f458a35915)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#coagadex "coagadex"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-acef8cbcdfca211b39877dbdf094e7e6) // coagadex en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-acef8cbcdfca211b39877dbdf094e7e6) // coagadex da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-acef8cbcdfca211b39877dbdf094e7e6
InstanceOf: List

* insert acef8cbcdfca211b39877dbdf094e7e6ListRuleset
    